F-1/A: Polyrizon Ltd. Files Amendment No. 5 to Form F-1 for Initial Public Offering

Polyrizon Ltd. is proceeding with its initial public offering, offering units consisting of ordinary shares and warrants, and pre-funded units, while also registering shares for resale by existing shareholders.

Summary

• Polyrizon Ltd., a development stage biotech company, has filed Amendment No. 5 to its Form F-1 registration statement.
• The company is planning an initial public offering (IPO) of units, each consisting of one ordinary share and three warrants, and pre-funded units, each consisting of one pre-funded warrant and three warrants.
• The IPO price per unit is expected to be between $ and $, with an assumed warrant exercise price of $ per share.
• The warrants will be immediately exercisable and expire five years from the issuance date.
• Pre-funded units are offered to purchasers who would otherwise exceed ownership limits of 4.99% (or 9.99%) of outstanding ordinary shares.
• The purchase price of each pre-funded unit will equal the price per unit, minus $0.001, and the exercise price of each pre-funded warrant will be $0.001 per ordinary share.
• The company has applied to list its ordinary shares on the Nasdaq Capital Market under the symbol PLRZ.
• The company is registered to allow certain shareholders to resell up to 1,044,242 ordinary shares.
• The company intends to use the net proceeds from this offering for preclinical and clinical development of its PL-14, PL-15 and PL-16 product candidates, in vitro feasibility studies of corticosteroid, benzodiazepine, and naloxone for its T&T platform technology product candidates, and for working capital and general corporate purposes and possible future acquisitions.
• The company has granted the underwriter an option to purchase additional Ordinary Shares and/or up to an additional Warrants and/or up to an additional Pre-Funded Warrants, within 45 days from the date of this prospectus to cover over-allotments, if any.

Sentiment

Score: 6

Explanation: The document presents a balanced view, highlighting both the company's potential and the risks associated with its business. The company is still in the development stage and has a history of losses, but it is pursuing innovative technologies and has secured collaborations.

Positives

• The company has a pipeline of product candidates in development.
• The company has collaborations with SciSparc Ltd. and NurExone Biologic Inc.
• The company's management team has extensive experience in the life sciences industry.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
• The company has never generated any revenue from product candidate sales and may never be profitable.
• The company expects that it will need to raise substantial additional funding, which may not be available on acceptable terms, or at all.

Risks

• The company's business is subject to a number of risks, including risks related to its financial condition, capital requirements, product candidate development, reliance on third parties, intellectual property, and business operations.
• The company is heavily dependent on the success of its C&C product candidates.
• Regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time-consuming and unpredictable.
• The company faces intense competition in an environment of rapid technological change.
• The company's headquarters and other significant operations are located in Israel, and, therefore, its results may be adversely affected by political, economic and military instability in Israel.

Future Outlook

The company expects expenses and operating losses to increase as it continues clinical development of its C&C product candidates and develops other product candidates using its T&T platform technology.

Industry Context

The document highlights the increasing market for nasal sprays and allergen blockers, indicating a growing demand for the types of products Polyrizon is developing.

Comparison to Industry Standards

• The document mentions Alzair Allergy Blocker (510(k) Number: K170848), NASAL EASE ALLERGY BLOCKER (510(k) Number: K132520), and Bentrio Allergy Blocker (510(k) Number: K213114) as predicate devices for the PL-14 product candidate.
• The FDA submission and clearance process for Alzair took 86 days, while Nasalese took 140 days, providing a benchmark for Polyrizon's expected timeline.

Related Party Transactions

• XYLO TECHNOLOGIES LTD. Share Purchase Agreements
• August 2021 Share Purchase Agreement
• June 2023, December 2023 and May 2024 Share Purchase Agreements
• Loans with XYLO
• Loan with Reuven Srugo Construction Company Ltd.

Stakeholder Impact

• Shareholders will be subject to potential dilution.
• Employees may benefit from equity incentive plans.
• Customers may benefit from new and innovative products.
• Suppliers and creditors may benefit from the company's growth and success.

Next Steps

• Initiate preclinical safety trials for PL-14, PL-15, and PL-16 product candidates in the first quarter of 2025.
• Commence pivotal clinical trial for PL-14 product candidate in the third quarter of 2025.
• Submit a 510(k) application to the FDA for PL-14 product candidate.
• Initiate feasibility clinical trials for PL-15 product candidate in the second quarter of 2026.
• Initiate pivotal clinical trials for PL-15 product candidate in the first quarter of 2027.
• Submit De Novo Classification requests for PL-15 and PL-16 product candidates.
• Conduct feasibility studies for T&T platform product candidates with corticosteroids, benzodiazepines, and naloxone, beginning in the third quarter of 2024 through the first quarter of 2026.
• Begin pre-clinical studies for T&T platform product candidates in the second quarter of 2026.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2027, subject to securing additional financing.

Key Dates

Keywords

IPO, initial public offering, Polyrizon, ordinary shares, warrants, pre-funded units, biotech, medical devices, nasal sprays, PLRZ